Agilus Diagnostics Ltd - Stock Valuation and Financial Performance

BSE: 0 | NSE: | Hospital & Healthcare Services | Small Cap

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Agilus Diagnostics

DeciZen not available for IPO

10 Year X-Ray of Agilus Diagnostics:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 3.9%6.6%7.9%7.9%6%6%6.5%8.8%13.1%7%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 432513585637681705714775966834677
Sales YoY Gr.-18.8%14.1%8.9%6.9%3.6%1.4%8.4%24.8%-13.7%-
Adj EPS 3.4810.49.77.17.4811.920.111.56.8
YoY Gr.-136.5%30.7%-7.1%-27.1%4.3%8%50.2%68.3%-42.9%-
BVPS (₹) 121.2128.9138.8126.9122.6130137.2149169.2174.8179.8
Adj Net
Profit
20.247.762.470.155.457.762.393.61589035
Cash Flow from Ops. 4865.112329.4-30.2-2.713513313477.2-
Debt/CF from Ops. 3.82.10.30.1-0.5-0.70000-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 7.6%4.1%5.3%-13.7%
Adj EPS 14.6%10.2%13%-42.9%
BVPS4.2%7.4%8.4%3.3%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
2.76.27.67.95.85.85.98.312.66.73.9
Op. Profit
Mgn %
14.316.918.817.614.714.215.316.920.211.9NAN
Net Profit
Mgn %
4.79.310.7118.18.28.712.116.310.85.2
Debt to
Equity
0.20.200000000-
Working Cap
Days
3412442152322442392542141321370
Cash Conv.
Cycle
2514182460956912-3-10

Recent Performance Summary

Recent Performance Summary not available for IPO

Recent Performance Summary not available for IPO

Latest Financials - Agilus Diagnostics Ltd.

Standalone Consolidated
TTM EPS (₹) 6.8 -
TTM Sales (₹ Cr.) 677 -
BVPS (₹.) 179.8 -
Reserves (₹ Cr.) 883 -
P/BV 0.00 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 0.00 / 0.00
All Time Low / High (₹) - / -
Market Cap (₹ Cr.) 0
Equity (₹ Cr.) 52
Face Value (₹) 10
Industry PE 84.6

Management X-Ray of Agilus Diagnostics:

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Agilus Diagnostics

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales431.67512.62585.04636.89680.55704.69714.21774.51966.44833.78
Operating Expenses 370.05426.01475.23525.39580.51604.47604.80643.73771.66734.52
Manufacturing Costs57.6714.7640.6744.2345.0420.6333.8823.2737.2845.94
Material Costs131.10149.12198.77215.65236.87185.24180.85230.80247.23213.14
Employee Cost 95.91116.43134.15149.90164.78172.47190.35184.21197.78195.80
Other Costs 85.37145.70101.64115.61133.83226.13199.72205.45289.38279.65
Operating Profit 61.6286.62109.81111.50100.03100.21109.40130.78194.7899.25
Operating Profit Margin (%) 14.3%16.9%18.8%17.5%14.7%14.2%15.3%16.9%20.2%11.9%
Other Income 26.4234.2135.6425.9821.8620.0331.6035.4457.7159.64
Interest 23.2819.3013.273.212.763.248.058.108.757.24
Depreciation 33.4730.1344.2928.0222.7419.4232.4631.8031.8136.38
Exceptional Items 00-3.540-28.30-2.81-6.62-1.380-14.77
Profit Before Tax 31.2871.4084.35106.2668.0994.7793.87124.94211.92100.50
Tax 11.2323.8324.2536.5132.6338.8936.1232.5054.3619.58
Profit After Tax 20.0547.5760.1069.7535.4655.8757.7592.44157.5780.92
PAT Margin (%) 4.6%9.3%10.3%11.0%5.2%7.9%8.1%11.9%16.3%9.7%
Adjusted EPS (₹)3.48.010.09.64.57.17.411.820.15.6
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 749.33795.64855.20926.38961.541,019.201,075.611,168.491,326.951,370.93
Share Capital 84.4684.4984.5280.3878.4278.4378.4378.4378.4378.43
Reserves 664.87711.15770.67845.99883.12940.77997.181,090.071,248.521,292.50
Minority Interest0000000000
Debt138.2197.389.872.3114.771.9900.851.151.53
Long Term Debt123.3486.69000000.851.151.53
Short Term Debt14.8710.709.872.3114.771.990000
Trade Payables39.2346.3355.0155.3256.2958.4662.3482.5686.3697.60
Others Liabilities 64.7562.7939.42146.9025.5631.3687.8186.58137.54139.87
Total Liabilities 991.521,002.15959.501,130.911,058.161,111.011,225.761,338.491,5521,609.93

Fixed Assets

Gross Block372.05380.97247.83283.08283.16290.44349.48399.30419.37445.41
Accumulated Depreciation108.29134.8222.7350.3164.4582.69101.17134.13148.97138.62
Net Fixed Assets263.76246.14225.11232.77218.71207.74248.32265.17270.40306.79
CWIP 5.463.533.071.100.451.880.130.901.571.14
Investments 391.24391.24391.29412.81400.19399.45393.03403.50752.18786.71
Inventories15.9817.6417.9117.5420.8917.3822.5029.9738.5144.35
Trade Receivables66.5379.6183.56124.53222.10309.66116.42119.07114.25110.89
Cash Equivalents 2.895.287.238.823.6314.0976.69266.60198.80152.08
Others Assets245.65258.71231.33333.35192.19160.82368.67253.29176.27207.97
Total Assets 991.521,002.15959.501,130.911,058.161,111.011,225.761,338.491,5521,609.93

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 47.9765.10123.3029.40-30.16-2.71134.90133.08133.5277.17
PBT 31.2871.4084.35106.2668.0994.7793.87124.94211.92100.50
Adjustment 35.7622.7731.0510.9240.1521.5719.7013.74-12.455.40
Changes in Working Capital -1.42-6.844.59-48.27-101.7-76.6459.5230.07-3.95-0.76
Tax Paid -17.65-22.223.31-39.51-36.71-42.41-38.18-35.67-62-27.96
Cash Flow From Investing Activity 12.124.34-9.554.6914.4828.07-123.8129.93-204.576.04
Capex -24.610.39-25.73-28.02-26.10-10.32-23.35-28.18-25.64-26.64
Net Investments 00000-1.33024.28-27.1277.67
Others 36.723.9516.1932.7140.5839.73-100.4633.83-151.81-44.99
Cash Flow From Financing Activity -63.49-66.85-112.43-24.32-2.01-2.56-17.79-18.88-18.33-57.89
Net Proceeds from Shares 00.120.121.420.260.030000
Net Proceeds from Borrowing -51.75-48.1100000000
Interest Paid -31.95-19.30-12.25-1.910-2.60-7.32-7.33-2.44-1.36
Dividend Paid 000000000-37.25
Others 20.210.44-100.30-23.83-2.260-10.46-11.55-15.89-19.28
Net Cash Flow -3.402.601.339.77-17.6922.80-6.69144.13-89.3925.32
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)2.816.367.517.983.775.645.518.2412.636
ROCE (%)5.829.7510.7312.027.419.779.6811.817.627.96
Asset Turnover Ratio0.430.510.60.610.620.650.610.60.670.53
PAT to CFO Conversion(x)2.391.372.050.42-0.85-0.052.341.440.850.95
Working Capital Days
Receivable Days5152516093138109554449
Inventory Days14121110101010121318
Payable Days101105939386113122115125158

Agilus Diagnostics Ltd Stock News

Agilus Diagnostics Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Agilus Diagnostics on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Agilus Diagnostics stood at ₹0.00.
The latest P/E ratio of Agilus Diagnostics as of 01-Jan-1970 05:30 is 0.00.
The latest P/B ratio of Agilus Diagnostics as of 01-Jan-1970 05:30 is 0.00.
The 52-week high of Agilus Diagnostics is ₹0.00 and the 52-week low is ₹0.00.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Agilus Diagnostics is ₹677.0 ( Cr.) .

About Agilus Diagnostics Ltd

Super Religare Laboratories Limited was initially incorporated on July 7, 1995 as specialty Ranbaxy Private Limited, 50:50 joint ventures between Specialty Laboratories Asia Limited and Ranbaxy Laboratories Limited, pursuant to a joint venture agreement dated April 17, 1995 (JV Agreement). Later the name of the company was subsequently changed to  SRL Ranbaxy Limited .The reason for such name change was the termination of the joint venture with Specialty Laboratories Asia Limited on January 18, 2002, consequent to which the company had to drop the trade name specialty  from its name, in accordance with the JV Agreement.

On August 20, 2010, the company acquired 100% of the paid up capital of Piramal Diagnostics Services Private Limited (PDSPL). The company was incorporated in order to undertake the business of establishing, maintaining and managing clinical reference laboratories to provide testing, diagnostic and prognostic monitoring services.

Business Profile:

The company is one of the leading diagnostics services companies in India. Following the acquisition of PDSPL in August 2010, we have the largest market share (48%) in the organized sector in India. The company provides diagnostic testing services (routine, specialized and esoteric tests), preventive care testing services and clinical research trial testing services at their laboratories, and during the nine month period ended December 31, 2010 it has performed approximately 33,000 diagnostic tests per day. It has served more than 4.20 million customers during the nine month period ended December 31, 2010 through their network of reference laboratories, Centers of Excellence, network laboratories (comprising pathology and radiology laboratories), collection centers and wellness centers. As of December 31, 2010, its diagnostic laboratory network comprised eight reference laboratories, seven Centers of Excellence, 181 network laboratories (comprising 164 pathology laboratories and 17 radiology laboratories), 15 wellness centers and 888 collection centers. As of December 31, 2010, of its 164 pathology laboratories, 53 are owned by the company, it operate and manage 31 pathology laboratories based in hospitals (14 of which are based in hospitals run by Fortis Healthcare Limited), 55 are joint venture laboratories and 25 are franchisee laboratories. As of December 31, 2010, of its 17 radiology laboratories, 16 are owned by them and we operate and manage one radiology laboratory based in a hospital. Six of its reference laboratories are based in India, its seventh reference laboratory is based in Kathmandu, Nepal and the company has entered into a service agreement for one reference laboratory in the Dubai Healthcare City.

In addition, currently it is having 23 collection centers, as well as representation and liaison offices, outside India in the United Arab Emirates, Oman, Qatar, Kuwait, Bahrain, Sri Lanka, Bangladesh, Nepal, the Maldives, Tanzania and Zambia.

The company’s reports are used for detection, diagnosis, evaluation, monitoring and treatment of diseases and other medical conditions, as well as to monitor and evaluate responses to medication. Through Piramal Diagnostics, it offer a range of pathology services and radiology modalities including computed tomography (CT), diagnostic radiology (X-ray), magnetic resonance imaging (MRI), ultrasound and positron emission tomography (PET). Its collection centers collect specimens within an area or region for shipment to a pre-designated laboratory for testing and its wellness centers offer inter alia preventive care through various health screening packages.

The company also provides clinical research services, which are dedicated to offering centralized laboratory services to support the needs of drug development for various phases of clinical trials conducted by Indian as well as international pharmaceutical, biotechnological and research companies. Its services extend to support multi-centric studies at sites within India as well as in their neighboring Asian countries.

Top 5 Group Companies:

  • Fortis Healthcare Limited
  • Fortis Malar Hospitals Limited
  • Religare Enterprises Limited
  • Dion Global Solutions Limited - one of the largest Group Company (based on turnover- Fiscal 2010)
  • Religare Securities Limited
Read More Read Less
You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.